A knockout Combo: eradicating AML Stem Cells with TKI plus SIRT1 inhibition.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 25280212.
- Also identified by DOI 10.1016/j.stem.2014.09.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
SIRT1 inhibition facilitates elimination of CML stem cells by Imatinib, in part via p53 activation. In this issue of Cell Stem Cell, Li et al. (2014) demonstrate a similar role for SIRT1 inhibition in eradicating FLT3-ITD AML stem cells, potentially through a positive feedback loop with c-MYC, highlighting SIRT1 as a potential target in combination cancer therapy.
Medical subject headings
- Drug Resistance, Neoplasm
- Gene Regulatory Networks
- Leukemia, Myeloid, Acute
- Neoplastic Stem Cells
- Proto-Oncogene Proteins c-myc
- Sirtuin 1
- fms-Like Tyrosine Kinase 3